About Chiral Emcure
Chiral Emcure is a company based in Pune (India) founded in 1981. It operates as a B2B and Outsourcing. The company has 6,877 employees as of March 31, 2024. Chiral Emcure offers products and services including APIs, Formulations, and Biotechnology Products. Chiral Emcure operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
- Headquarter Pune, India
- Employees 6877 as on 31 Mar, 2024
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Emcure Pharmaceuticals Limited
- Jurisdiction Pune City, Maharashtra, India
-
Annual Revenue
$784.49 M (USD)11.33as on Mar 31, 2024
-
Net Profit
$61.63 M (USD)-6.1as on Mar 31, 2024
-
EBITDA
$143.66 M (USD)4.11as on Mar 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
6877
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Chiral Emcure
Chiral Emcure offers a comprehensive portfolio of products and services, including APIs, Formulations, and Biotechnology Products.
Production of active pharmaceutical ingredients for drug development.
Creation of finished pharmaceutical products for various applications.
Development of biotechnology-based pharmaceuticals and solutions.
Funding Insights of Chiral Emcure
Investments & Acquisitions by Chiral Emcure
Financial Statements - Chiral Emcure
Chiral Emcure Comparisons
Competitors of Chiral Emcure
Chiral Emcure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Integrated CDMO services for biopharma R&D and manufacturing are offered.
|
|
| domain | founded_year | HQ Location |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| domain | founded_year | HQ Location |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| domain | founded_year | HQ Location |
APIs and finished products are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
|
| domain | founded_year | HQ Location |
APIs and peptides are developed and manufactured by Asymchem.
|
Latest news on Chiral Emcure
Frequently Asked Questions about Chiral Emcure
Chiral Emcure was founded in 1981.
Chiral Emcure is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
As of Mar 31, 2024, the latest employee count at Chiral Emcure is 6,877.
Annual revenue of Chiral Emcure is $784.49M as on Mar 31, 2024.
Emcure is a vertically integrated pharmaceutical company that conducts research and manufacturing of active pharmaceutical ingredients (APIs), formulations, and biotechnology products. It serves as a preferred outsourcing partner for major multinational corporations in India and international markets. Based in Pune, India, the company focuses on high-quality production and innovation, while adhering to industry standards and partnering with global entities for distribution and development.
Chiral Emcure's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
Chiral Emcure offers APIs, Formulations, and Biotechnology Products.